Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Kallyope’s focus on the gut-brain axis yields a diverse portfolio

By Brian Buntz | August 4, 2022

KallyopeNew York City-based Kallyope is one of the few biotechs focused solely on the gut-brain axis. 

The privately-held company has built a cross-disciplinary team that weaves together advanced technologies in sequencing, bioinformatics, neural imaging, human genetics, and cellular and molecular biology to interrogate the hormonal and neural signaling pathways that comprise the gut-brain axis. 

The company has raised $479 million to date, including a $236 million Series D financing in February.

Jay Galeota

Jay Galeota

The president and CEO of the company is Jay Galeota, who worked at Merck & Co. (NYSE:MRK) for almost three decades.  

“I was fortunate enough to lead the team that brought Merck into diabetes with Januvia (sitagliptin) and Janumet (sitagliptin/metformin),” Galeota said. Last year, the drugs generated $5.3 billion in revenue.

The discoverers of sitagliptin, Nancy Thornberry and Ann Weber, are both Merck alumni who are now senior executives at Kallyope. Thornberry was the founding CEO of the biotech and currently serves as chair of R&D, while Weber is a senior vice president of preclinical development. 

A wet-lab-equipped office in Manhattan

The focus on science was part of what drew Galeota in. “When you come off the elevator on our floor in this tower in New York City, you think you’re in an academic wet lab,” Galeota said. “You see all around hoods and the equipment and everything. Almost 90% of our employees are scientists, which is super exciting.” 

Galeota said the company is a “lab as much as we are a biopharma company.” 

Kallyope has explored using novel biology and basic science to unlock previously unknown neural signaling pathways between the gastrointestinal (GI) tract and the brain. 

The goal is to map the neural and hormonal signaling pathways between the GI tract and the brain to learn how to elicit systemic responses that have a therapeutic effect. “Based on this work, the targets were identified and validated,” Galeota said. 

Kallyope’s pipeline

The company is now focusing in three distinct therapeutic areas. 

The first area focuses on metabolism and metabolic circuits. “That is specifically in diabetes and obesity, but also other related conditions,” Galeota explained. “We have compounds in the clinic in that area, and we have follow-on compounds that are in development.”

Kallyope pipeline

[Image courtesy of Kallyope]

The second area focuses broadly on gut disorders, specifically targeting the cellular junctions in the epithelium that comprise the gut barrier. “Barrier function is relevant to a number of gastrointestinal disorders and other disease states”” Galeota said. 

The company’s neurobiology franchise spans multiple disease areas. “We’ve got a lead program in migraine that we’re super excited about,” Galeota said. “Our chief medical officer led the early clinical development of two migraine programs at Merck. Then we’ve got several follow-on compounds in other areas like Parkinson’s disease and neuroinflammation.”

In the long run, the company sees many other potential diseases its pipeline could address, including conditions ranging from food allergy and celiac disease to rare diseases.


Filed Under: clinical trials, Drug Discovery, Gastroenterology, Metabolic disease/endicrinology, Psychiatric/psychotropic drugs
Tagged With: gut-brain axis, Kallyope, Merck
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Austrian researchers find IgA-tagged vesicles turn gut’s own antibodies against it, worsening ulcerative colitis
One of C. difficile’s metabolic powers might be turning a toxin into a fuel
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years
Lumen Bioscience
How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE